Cross-Market Price Comparison
| Other Listed Market | Shanghai (SSE) — 复星医药 |
|---|---|
| Other Market Stock Code | 600196 |
| H-Share Offer Price | To be extracted |
| Other Market Price | Loading... |
| Reference Exchange Rate | Loading... |
| H-Share Offer Price Premium/Discount vs Other Market | Loading... |
Company Overview
| Stock Name | 上海復星醫藥(集團)股份有限公司 － Ｈ股 |
|---|---|
| Stock Code | 02196 |
| Company Full Name | 上海復星醫藥(集團)股份有限公司 － Ｈ股 |
| Industry | 醫療保健 |
| Principal Activities | 主要從事開發、制造和銷售醫藥產品和醫療設備、進出口醫療設備和提供相關及其他諮詢服務以及投資管理。 |
| Listing Date | 2012-10-30 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市普陀區曹楊路510號9樓 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.fosunpharma.com |
| Share Registrar | |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 11.80 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 14.6% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 778,800,000 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 10.84 |
|---|---|
| First Day Open | HK$ 11.08 |
| First Day Change | -8.14% |
| First Day Volume | 54273500.0 |
| First Day Turnover | 588861000.0 |
Use of Proceeds
| Use of Proceeds | 1、約48%或1,806.9百萬港元將用于制藥、醫藥分銷及零售、醫藥健康、診斷產品及醫療器械領域的收購及合并； 2、約19%或715.2百萬港元將用于為現有的研發項目、擴充我們的研發團隊及收購新的研發項目融資； 3、約23%或865.8百萬港元將用于償還本集團的部分帶息負債的本金及利息； 4、約10%或376.4百萬港元將用于補充本集團的營運資金。 |
|---|
Underwriting Syndicate
Joint Sponsors (4)
UBS Securities Hong Kong Limited CE BIN466
中国国际金融香港证券有限公司 CE AEN894
J.P. Morgan Securities (Far East) Limited CE AAB026
德意志银行香港分行
Overall Coordinators (4)
UBS Securities Hong Kong Limited CE BIN466
中国国际金融香港证券有限公司 CE AEN894
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
德意志银行香港分行
Joint Bookrunners (4)
UBS Securities Hong Kong Limited CE BIN466
中国国际金融香港证券有限公司 CE AEN894
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
德意志银行香港分行
Joint Lead Managers (4)
UBS Securities Hong Kong Limited CE BIN466
中国国际金融香港证券有限公司 CE AEN894
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
德意志银行香港分行
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | The Prudential Insurance Company of America | 387,624,100 HKD | — | 9.77% | — | 6 months | 2013-04-30 |
| 2 | 国际金融公司 | 191,160,000 HKD | — | 4.82% | — | 6 months | 2013-04-30 |
Directors & Management
| Chairman | 陳玉卿,關曉暉 |
|---|---|
| Company Secretary | 董曉嫻,陳秀玲 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 復星國際有限公司(60.70%);貝萊德(4.97%) |
|---|
